Is immunotherapy in the future of therapeutic management of sarcomas?


Journal

Journal of translational medicine
ISSN: 1479-5876
Titre abrégé: J Transl Med
Pays: England
ID NLM: 101190741

Informations de publication

Date de publication:
26 04 2021
Historique:
received: 25 01 2021
accepted: 12 04 2021
entrez: 27 4 2021
pubmed: 28 4 2021
medline: 15 5 2021
Statut: epublish

Résumé

Sarcomas are rare, ubiquitous and heterogeneous tumors usually treated with surgery, chemotherapy, target therapy, and radiotherapy. However, 25-50% of patients experience local relapses and/or distant metastases after chemotherapy with an overall survival about 12-18 months. Recently, immuno-therapy has revolutionized the cancer treatments with initial indications for non-small cell lung cancer (NSCLC) and melanoma (immune-checkpoint inhibitors).Here, we provide a narrative review on the topic as well as a critical description of the currently available trials on immunotherapy treatments in patients with sarcoma. Given the promising results obtained with anti-PD-1 monoclonal antibodies (pembrolizumab and nivolumab) and CAR-T cells, we strongly believe that these new immunotherapeutic approaches, along with an innovative characterization of tumor genetics, will provide an exciting opportunity to ameliorate the therapeutic management of sarcomas.

Identifiants

pubmed: 33902630
doi: 10.1186/s12967-021-02829-y
pii: 10.1186/s12967-021-02829-y
pmc: PMC8077947
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

173

Références

EBioMedicine. 2019 Sep;47:89-97
pubmed: 31409575
Clin Cancer Res. 2000 Aug;6(8):3342-53
pubmed: 10955822
Nat Rev Drug Discov. 2019 Sep;18(9):689-706
pubmed: 31292532
Methods Mol Biol. 2020;2058:1-6
pubmed: 31486028
Am Soc Clin Oncol Educ Book. 2016;35:e558-64
pubmed: 27249767
Science. 2011 Mar 25;331(6024):1565-70
pubmed: 21436444
Mod Pathol. 2014 Sep;27(9):1238-45
pubmed: 24457462
Nature. 2007 Mar 8;446(7132):153-8
pubmed: 17344846
Clin Sarcoma Res. 2016 Dec 30;6:24
pubmed: 28042471
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Nat Biotechnol. 2005 Mar;23(3):349-54
pubmed: 15723046
Onco Targets Ther. 2019 Aug 23;12:6887-6896
pubmed: 31692518
J Pathol. 2016 Jan;238(1):63-73
pubmed: 26365879
Sarcoma. 2013;2013:168145
pubmed: 23554566
Cancers (Basel). 2020 Jul 11;12(7):
pubmed: 32664595
Oncoimmunology. 2018 Sep 11;7(12):e1507600
pubmed: 30524904
Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10972-7
pubmed: 20534461
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10697-702
pubmed: 15252201
J Bone Miner Res. 2014 Oct;29(10):2287-96
pubmed: 24737304
Cancer Treat Rev. 2020 Jan;82:101934
pubmed: 31794912
J Immunother Cancer. 2018 May 14;6(1):35
pubmed: 29754585
J Biol Chem. 1987 Nov 5;262(31):14855-8
pubmed: 2822703
South Asian J Cancer. 2016 Jan-Mar;5(1):15-9
pubmed: 27169114
Br J Cancer. 2011 Jun 28;105(1):93-103
pubmed: 21629244
Lancet Oncol. 2017 Nov;18(11):1493-1501
pubmed: 28988646
J Transl Med. 2005 Jan 12;3(1):1
pubmed: 15647119
Sci Transl Med. 2013 Aug 7;5(197):197ra103
pubmed: 23926201
Cancer Sci. 2012 Sep;103(9):1625-30
pubmed: 22726592
Nat Immunol. 2002 Nov;3(11):991-8
pubmed: 12407406
Front Oncol. 2020 Apr 15;10:509
pubmed: 32351891
Ann Oncol. 2014 Mar;25(3):611-618
pubmed: 24401929
Future Oncol. 2020 Jun;16(17):1211-1223
pubmed: 32396026
J Clin Oncol. 2017 Sep 10;35(26):3010-3020
pubmed: 28715249
Oncotarget. 2015 May 20;6(14):12234-47
pubmed: 25906748
Clin Sarcoma Res. 2017 Aug 22;7:16
pubmed: 28852467
Genes Dev. 2018 Oct 1;32(19-20):1267-1284
pubmed: 30275043
Nature. 2011 Aug 31;477(7362):99-102
pubmed: 21886163
Lancet Oncol. 2018 Mar;19(3):416-426
pubmed: 29370992
Cancers (Basel). 2018 Dec 20;11(1):
pubmed: 30577459
Pathol Res Pract. 2005;201(4):347-53
pubmed: 15991843
Lancet Oncol. 2017 Mar;18(3):e166-e175
pubmed: 28271871
J Clin Oncol. 2010 Jan 1;28(1):105-13
pubmed: 19917869
Lab Invest. 2018 Jan;98(1):41-50
pubmed: 29155424
JCO Precis Oncol. 2017;2017:
pubmed: 29850653
EBioMedicine. 2018 May;31:17-24
pubmed: 29724655
Immunotherapy. 2018 Feb;10(2):149-160
pubmed: 29260623
Hum Pathol. 2015 Mar;46(3):357-65
pubmed: 25540867
N Engl J Med. 2015 Nov 12;373(20):1979
pubmed: 26559583
Cancer. 2012 Sep 15;118(18):4564-70
pubmed: 22359263
PLoS One. 2013 Dec 02;8(12):e79775
pubmed: 24312450
J Clin Oncol. 2003 Apr 15;21(8):1498-504
pubmed: 12697873
Front Med (Lausanne). 2020 Mar 24;7:90
pubmed: 32266275
Immunity. 1998 Apr;8(4):413-25
pubmed: 9586632
Int J Cancer. 2001 Oct 15;94(2):252-6
pubmed: 11668506
Head Neck. 2005 Oct;27(10):883-92
pubmed: 16158422
Nat Rev Cancer. 2011 Jul 14;11(8):541-57
pubmed: 21753790
Nat Rev Clin Oncol. 2019 Mar;16(3):151-167
pubmed: 30523282
Blood. 2017 Nov 23;130(21):2295-2306
pubmed: 28924019
J Clin Oncol. 1999 Jan;17(1):150-7
pubmed: 10458228
Elife. 2019 Nov 26;8:
pubmed: 31767055
Lancet Oncol. 2017 Nov;18(11):1430-1431
pubmed: 28988645
Eur J Cancer. 2005 Jun;41(9):1349-61
pubmed: 15913990
J Immunol Res. 2016;2016:4273943
pubmed: 28116316
Am J Surg Pathol. 1997 May;21(5):518-27
pubmed: 9158675
Ann Surg. 1999 May;229(5):602-10; discussion 610-2
pubmed: 10235518
Ann Oncol. 1991 Apr;2(4):307-9
pubmed: 1868027
Int J Cancer. 2017 Sep 15;141(6):1257-1264
pubmed: 28568891
Expert Rev Anticancer Ther. 2012 Feb;12(2):229-42
pubmed: 22316371
Cancer. 1981 May 15;47(10):2391-7
pubmed: 7272893
Ther Adv Hematol. 2019 Apr 15;10:2040620719841581
pubmed: 31019670
Sarcoma. 2014;2014:391967
pubmed: 24778572
Clin Cancer Res. 2000 Dec;6(12):4658-62
pubmed: 11156217
Nat Rev Clin Oncol. 2020 Feb;17(2):73-74
pubmed: 31907372
Surg Clin North Am. 2016 Oct;96(5):901-14
pubmed: 27542634
Curr Opin Immunol. 2014 Apr;27:16-25
pubmed: 24531241
J Clin Oncol. 2003 Jun 15;21(12):2415-32
pubmed: 12805342
Oncoimmunology. 2017 Nov 20;7(3):e1389366
pubmed: 29399389
PLoS One. 2012;7(2):e32165
pubmed: 22384167
Science. 2018 Mar 23;359(6382):1361-1365
pubmed: 29567707
Cancer J. 2018 Jan/Feb;24(1):47-53
pubmed: 29360728
Ann Oncol. 2018 Apr 1;29(4):1067-1069
pubmed: 29324995
J Exp Med. 1998 Apr 20;187(8):1349-54
pubmed: 9547346
Immunology. 2007 May;121(1):1-14
pubmed: 17386080
J Surg Oncol. 2011 Apr;103(5):380-5
pubmed: 21400519
J Clin Invest. 2014 Feb;124(2):687-95
pubmed: 24382348
Clin Cancer Res. 2019 Oct 1;25(19):5808-5817
pubmed: 31227504
Front Immunol. 2018 May 01;9:947
pubmed: 29770138
Cancer Res Treat. 2018 Oct;50(4):1458-1461
pubmed: 29361819
BMC Cancer. 2016 Jul 08;16:434
pubmed: 27393385
Lancet Oncol. 2008 Jun;9(6):533-42
pubmed: 18495536
N Engl J Med. 2018 May 31;378(22):2093-2104
pubmed: 29658845
Mol Med Rep. 2012 Feb;5(2):457-61
pubmed: 22052239
Melanoma Res. 2008 Feb;18(1):47-55
pubmed: 18227708
Anticancer Res. 2005 Nov-Dec;25(6C):4519-26
pubmed: 16334136
N Am J Med Sci. 2016 May;8(5):210-4
pubmed: 27298815
Arch Surg. 1990 Feb;125(2):200-5
pubmed: 1689143
Cancer Sci. 2006 Dec;97(12):1374-80
pubmed: 16995877
Cancer. 2016 Oct;122(19):2952-60
pubmed: 27434055
Cancer Immunol Immunother. 2015 Oct;64(10):1251-60
pubmed: 26105625
Cell. 2013 Mar 28;153(1):71-85
pubmed: 23540691
J Immunother. 2021 Feb-Mar 01;44(2):63-70
pubmed: 33443972
Med Pediatr Oncol. 2002 Mar;38(3):158-64
pubmed: 11836714
Oncoimmunology. 2018 Mar 15;7(7):e1442168
pubmed: 29900051
Contemp Oncol (Pozn). 2018 Mar;22(1A):61-67
pubmed: 29628796
Cancer Immun. 2004 Aug 09;4:7
pubmed: 15298487
Cancer Res. 2013 Jun 15;73(12):3499-510
pubmed: 23592754
Hum Pathol. 2017 Mar;61:130-139
pubmed: 27993576
Cancers (Basel). 2019 May 15;11(5):
pubmed: 31096717
N Engl J Med. 2015 Nov 12;373(20):1979
pubmed: 26559582
Clin Transl Oncol. 2016 Dec;18(12):1213-1220
pubmed: 27905051
N Engl J Med. 2017 Oct 12;377(15):1409-1412
pubmed: 29020592
Hematol Oncol. 2019 Jun;37 Suppl 1:95-100
pubmed: 31187533
J Clin Oncol. 2002 Mar 15;20(6):1562-9
pubmed: 11896105
J Eur Acad Dermatol Venereol. 2010 Nov;24(11):1326-32
pubmed: 20337820
J Pathol. 2011 Feb;223(3):347-57
pubmed: 21171080
J Clin Oncol. 2015 May 20;33(15):1688-96
pubmed: 25800760
J Pediatr Hematol Oncol. 2002 Aug-Sep;24(6):447-53
pubmed: 12218591
Oncoimmunology. 2017 Jan 27;6(3):e1279777
pubmed: 28405504
PLoS One. 2011 Jan 27;6(1):e14611
pubmed: 21298041
Immunity. 1995 Feb;2(2):167-75
pubmed: 7895173
J Immunother. 2013 Feb;36(2):133-51
pubmed: 23377668
J Hematol Oncol. 2018 Jan 03;11(1):1
pubmed: 29298689
Ann Surg Oncol. 2017 Aug;24(8):2145-2154
pubmed: 28397189
N Engl J Med. 2010 Jul 29;363(5):411-22
pubmed: 20818862
J Transl Med. 2020 Mar 27;18(1):140
pubmed: 32220256
Eur J Cancer. 2016 Nov;68:134-147
pubmed: 27755997
J Allergy Clin Immunol. 2010 Feb;125(2 Suppl 2):S3-23
pubmed: 20176265
Methods Mol Biol. 2009;542:705-17
pubmed: 19565928
J Immunother Cancer. 2019 Oct 24;7(1):276
pubmed: 31651363
Science. 1996 Jun 7;272(5267):1470-3
pubmed: 8633237
J Leukoc Biol. 2008 Oct;84(4):988-93
pubmed: 18515327
Melanoma Res. 2019 Apr;29(2):109-118
pubmed: 30802228
Int J Cancer. 1991 Dec 2;49(6):893-9
pubmed: 1959994
J Urol. 1976 Aug;116(2):180-3
pubmed: 820877
Clin Sarcoma Res. 2017 Jun 15;7:11
pubmed: 28630682
J Exp Med. 1999 Feb 1;189(3):461-70
pubmed: 9927508
Mod Pathol. 2012 Jun;25(6):854-8
pubmed: 22388761
Lancet Oncol. 2017 Jun;18(6):792-802
pubmed: 28395880
Open Access Maced J Med Sci. 2018 Sep 04;6(9):1555-1560
pubmed: 30337965
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
Cancer Immunol Res. 2014 Jan;2(1):37-49
pubmed: 24535937
Science. 2018 Feb 2;359(6375):582-587
pubmed: 29217585
Int J Cancer. 2001 Jul 1;93(1):85-90
pubmed: 11391626
Lancet Oncol. 2018 Mar;19(3):405-415
pubmed: 29439857
AIDS Rev. 2010 Jan-Mar;12(1):40-51
pubmed: 20216909
Am J Clin Dermatol. 2017 Feb;18(1):1-15
pubmed: 27988837
J Clin Oncol. 2003 Jul 15;21(14):2719-25
pubmed: 12860950
Oncologist. 2018 Jan;23(1):71-83
pubmed: 28935774
Mod Pathol. 2019 Jul;32(7):977-987
pubmed: 30765880
Sarcoma. 2016;2016:9757219
pubmed: 27703409
Curr Oncol. 2007 Dec;14(6):238-45
pubmed: 18080016
Lancet Oncol. 2014 Apr;15(4):415-23
pubmed: 24618336

Auteurs

Ottavia Clemente (O)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy.

Alessandro Ottaiano (A)

Division of Innovative Therapies, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy.

Giuseppe Di Lorenzo (G)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy.

Alessandra Bracigliano (A)

Nuclear Medicine Unit, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale, 80131, Naples, Italy.

Sabrina Lamia (S)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy.

Lucia Cannella (L)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy.

Antonio Pizzolorusso (A)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy.

Massimiliano Di Marzo (M)

Department of Abdominal Oncology, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy.

Mariachiara Santorsola (M)

Division of Innovative Therapies, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy.

Annarosaria De Chiara (A)

Histopathology of Lymphomas and Sarcomas SSD, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy.

Flavio Fazioli (F)

Orthopedic Oncology Unit, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy.

Salvatore Tafuto (S)

Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori, IRCCS - Fondazione "G. Pascale", 80131, Naples, Italy. s.tafuto@istitutotumori.na.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH